<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39268964</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Pharmacogenomics and pediatric drug development: science and political power. A narrative review.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14656566.2024.2401429</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Pharmacogenomics (PGx) investigates how genomes control enzyme expression. Developmental pharmacology (DP) describes the temporal sequence of enzymes impacting absorption, distribution, metabolism, and excretion (ADME) of food and drugs.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">US and European Union (EU) legislation facilitate and/or enforce pediatric studies for all new drugs, called overall 'pediatric drug development' (PDD). DP and PDD look at patients' chronological age, but oscillate between legal and physiological meanings of the term 'child.' Children's bodies become mature with puberty.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">Decades after first DP observations in babies, PGx offers a better understanding of the variability of safety and efficacy of drugs, of the process of aging, and of shifting enzyme patterns across aging. We should rethink and revise outdated interpretations of ADME changes in minors. The Declaration of Helsinki forbids pointless studies that some pediatric researchers and regulatory agencies, more so the EMA than the FDA, demand pointless pediatric studies is regrettable. Medicine needs to differentiate between legal and physiological meanings of the term 'child' and should use objective measures of maturity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ettienne</LastName><ForeName>Earl B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-5859-3086</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Howard University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant-Kels</LastName><ForeName>Jane M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-1844-8415</Identifier><AffiliationInfo><Affiliation>Dermatology, Pathology, and Pediatric Dermatology, University of Connecticut Health Center, Farmington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Striano</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6065-1476</Identifier><AffiliationInfo><Affiliation>University of Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1279-8123</Identifier><AffiliationInfo><Affiliation>Pharmacology, University of Magna Graecia, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neubauer</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4564-5318</Identifier><AffiliationInfo><Affiliation>Department of Child, Adolescent &amp; Developmental Neurology, University Childrens' Hospital, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8304-1822</Identifier><AffiliationInfo><Affiliation>klausrose Consulting, Riehen, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Better medicines for children (BMfC)</Keyword><Keyword MajorTopicYN="N">children as “therapeutic orphans“</Keyword><Keyword MajorTopicYN="N">conflict of interests (CoI)</Keyword><Keyword MajorTopicYN="N">developmental pharmacology</Keyword><Keyword MajorTopicYN="N">ethics committees</Keyword><Keyword MajorTopicYN="N">institutional review boards (IRBs)</Keyword><Keyword MajorTopicYN="N">pediatric drug development (PDD)</Keyword><Keyword MajorTopicYN="N">pharmacogenomics (PGX)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>14</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>14</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39268964</ArticleId><ArticleId IdType="doi">10.1080/14656566.2024.2401429</ArticleId></ArticleIdList></PubmedData></PubmedArticle>